一种新的癌症药物显示,南非一名患有小细胞肺癌的病人迅速成为肿瘤的目标,为美国从2025年底开始的试验铺平了道路。 A new cancer drug showed rapid tumor targeting in a South African patient with small cell lung cancer, paving the way for a U.S. trial starting late 2025.

分子伙伴分享了南非一名患有小细胞肺癌的病人提供的最初人类成像数据,该病人用MP0712治疗了细胞肺癌,这是一种针对DLL3的放射治疗药物,显示在24小时内使用同位素203Pb迅速和持续地吸收肿瘤,在健康器官中蓄积的程度极小。 Molecular Partners shared initial human imaging data from a South African patient with small cell lung cancer treated with MP0712, a radiotherapy drug targeting DLL3, showing rapid and sustained tumor uptake within 24 hours using the isotope 203Pb, with minimal accumulation in healthy organs. 结果支持了MP0712的机制,由于快速内部化和再循环,可以将高肿瘤作为低水平的DLL3目标,即使低水平的DLL3也能成为目标。 The results support MP0712’s mechanism, which enables high tumor targeting even at low DLL3 levels due to rapid internalization and recycling. 公司已向美国食品和药物管理局提交一期IND申请, The company has filed a Phase 1 IND application with the FDA, and a U.S. 第1/2a阶段试验,包括成像和剂量测量,预计到2025年底开始,初步数据预计到2026年。 Phase 1/2a trial, including imaging and dosimetry, is expected to start by year-end 2025, with initial data anticipated in 2026.